Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 11/20 | 0.55 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.46 |
| ▸ | PRKCH | P24723 | 1/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2975973 | 0.91 | PRKCQ (0.55) | PRKCQSYKPRKCDPRKCHPRKCE | |
| SCHEMBL17255765 | 0.83 | PRKCQ (0.50) | PRKCQPRKCDPRKCHPRKCELRRK2 | |
| SCHEMBL2986283 | 0.80 | PRKCQ (0.56) | PRKCQPRKCDPRKCHPRKCELRRK2 | |
| SCHEMBL2984264 | 0.74 | HPGD (0.52) | PRKCQSYKPRKCDESR1 | |
| SCHEMBL7204879 | 0.74 | PRKCQ (0.47) | PRKCQSYKPRKCDESR1LRRK2 | |
| SCHEMBL8788688 | 0.74 | SYK (0.50) | PRKCQSYKESR1CYP19A1FGFR2 | |
| SCHEMBL2980463 | 0.73 | PRKCQ (0.52) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL5621596 | 0.72 | SYK (0.44) | PRKCQSYKFGFR2FLT3 | |
| SCHEMBL2985305 | 0.72 | PRKCQ (0.64) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL8548736 | 0.72 | FGFR2 (0.55) | PRKCQSYKPRKCDFGFR2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | PRKCQ 165/4885SYK 414/4885PRKCD 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.